Work

A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.7111

Authors: Koji Sasaki, Jason R. Gotlib, Ruben A. Mesa, Farhad Ravandi, Jorge E. Cortes, Patrick Francis Kelly, Jeffrey Lorne Kutok, Hagop M. Kantarjian, Srdan Verstovsek

Institutions: The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University, Mayo Clinic, Mayo Clinic in Arizona, Infinity Pharmaceuticals (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2605116010

Cites:

Cited by: 3

Related to: 10